1
|
Flores-Velázquez LM, Ruiz-Campillo MT, Herrera-Torres G, Martínez-Moreno Á, Martínez-Moreno FJ, Zafra R, Buffoni L, Rufino-Moya PJ, Molina-Hernández V, Pérez J. Fasciolosis: pathogenesis, host-parasite interactions, and implication in vaccine development. Front Vet Sci 2023; 10:1270064. [PMID: 38149297 PMCID: PMC10750376 DOI: 10.3389/fvets.2023.1270064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Accepted: 10/30/2023] [Indexed: 12/28/2023] Open
Abstract
Fasciola hepatica is distributed worldwide, causing substantial economic losses in the animal husbandry industry. Human fasciolosis is an emerging zoonosis in Andean America, Asia, and Africa. The control of the disease, both in humans and animals, is based on using anthelmintic drugs, which has resulted in increased resistance to the most effective anthelmintics, such as triclabendazole, in many countries. This, together with the concerns about drug residues in food and the environment, has increased the interest in preventive measures such as a vaccine to help control the disease in endemic areas. Despite important efforts over the past two decades and the work carried out with numerous vaccine candidates, none of them has demonstrated consistent and reproducible protection in target species. This is at least in part due to the high immunomodulation capacity of the parasite, making ineffective the host response in susceptible species such as ruminants. It is widely accepted that a deeper knowledge of the host-parasite interactions is needed for a more rational design of vaccine candidates. In recent years, the use of emerging technologies has notably increased the amount of data about these interactions. In the present study, current knowledge of host-parasite interactions and their implication in Fasciola hepatica vaccine development is reviewed.
Collapse
Affiliation(s)
- Luis Miguel Flores-Velázquez
- Unidad de Anatomía, Histología y Patología Veterinaria, Escuela de Medicina Veterinaria, Facultad de Ciencias Naturales, Universidad San Sebastián, Campus Puerto Montt, Puerto Montt, Chile
| | - María Teresa Ruiz-Campillo
- Departamento de Anatomía y Anatomía Patológica Comparadas y Toxicología, UIC Zoonosis y Enfermedades Emergentes ENZOEM, Universidad de Córdoba, Córdoba, Spain
| | - Guillem Herrera-Torres
- Departamento de Anatomía y Anatomía Patológica Comparadas y Toxicología, UIC Zoonosis y Enfermedades Emergentes ENZOEM, Universidad de Córdoba, Córdoba, Spain
| | - Álvaro Martínez-Moreno
- Departamento de Sanidad Animal (Área de Parasitología), UIC Zoonosis y Enfermedades Emergentes ENZOEM, Universidad de Córdoba, Córdoba, Spain
| | - Francisco Javier Martínez-Moreno
- Departamento de Sanidad Animal (Área de Parasitología), UIC Zoonosis y Enfermedades Emergentes ENZOEM, Universidad de Córdoba, Córdoba, Spain
| | - Rafael Zafra
- Departamento de Sanidad Animal (Área de Parasitología), UIC Zoonosis y Enfermedades Emergentes ENZOEM, Universidad de Córdoba, Córdoba, Spain
| | - Leandro Buffoni
- Departamento de Sanidad Animal (Área de Parasitología), UIC Zoonosis y Enfermedades Emergentes ENZOEM, Universidad de Córdoba, Córdoba, Spain
| | - Pablo José Rufino-Moya
- Departamento de Sanidad Animal (Área de Parasitología), UIC Zoonosis y Enfermedades Emergentes ENZOEM, Universidad de Córdoba, Córdoba, Spain
| | - Verónica Molina-Hernández
- Departamento de Anatomía y Anatomía Patológica Comparadas y Toxicología, UIC Zoonosis y Enfermedades Emergentes ENZOEM, Universidad de Córdoba, Córdoba, Spain
| | - José Pérez
- Departamento de Anatomía y Anatomía Patológica Comparadas y Toxicología, UIC Zoonosis y Enfermedades Emergentes ENZOEM, Universidad de Córdoba, Córdoba, Spain
| |
Collapse
|
2
|
Cwiklinski K, McEvoy A, López Corrales J, Jewhurst H, Calvani NED, De Marco Verissimo C, Dorey AL, Keane OM, Dalton JP, Lalor R. Fasciola hepatica antioxidant and protease-inhibitor cocktail recombinant vaccines administered five times elicit potent and sustained immune responses in sheep but do not confer protection. Vet Parasitol 2023; 323:110049. [PMID: 37826973 DOI: 10.1016/j.vetpar.2023.110049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 09/27/2023] [Accepted: 10/07/2023] [Indexed: 10/14/2023]
Abstract
Our laboratory's vaccine development strategy against the livestock parasite Fasciola hepatica centres around disrupting key biological processes by combining groups of antigens with similar/complementary functional actions into a single vaccine cocktail. In this study the focus was on antioxidant protein vaccines and a protease inhibitor vaccine aimed at disrupting the parasite's ability to defend against oxidative stress and protease-inhibitor balance, respectively. Two combinations of recombinantly expressed antioxidants were assessed, namely peroxiredoxin (rFhPrx), thioredoxin (rFhTrx) and thioredoxin-glutathione reductase (rFhTGR) (Group 1) and rFhPrx, rFhTrx, and two superoxide dismutases (rFhSOD1 and rFhSOD3) (Group 2). The protease inhibitor vaccine cocktail included representatives of each of the key secreted protease inhibitor families, namely a Kunitz-type inhibitor (rFhKT1), a serpin (rFhSrp1) and a stefin, (rFhStf1) (Group 3). The vaccine combinations were formulated in adjuvant Montanide 61VG administered at five timepoints; two before experimental challenge with 60 F. hepatica metacercariae and three after infection. The vaccine combinations did not reduce the liver fluke burden, and only Group 2 displayed a marginal reduction in egg viability (8.2%). Despite previous results showing an effect of liver fluke vaccines on overall weight gain in infected animals, no significant (P value >0.05) impact on weight gain was observed in this study. Antibodies were elicited against all the vaccine antigens within the cocktails and were maintained at high levels to the end of the trial, due to our strategy of continuing vaccine administration after infection. However, these responses were not boosted by the challenge F. hepatica infection. A comparative analysis with previous vaccine data using a protease inhibitor vaccine found no repeat of the promising outcomes associated with this vaccine, indicating that the addition of rFhSrp1 to the vaccine cocktail did not improve vaccine efficacy. Assessment of liver pathology across the two trials using a modified liver enzyme score (glutamate dehydrogenase to platelet ratio) at eight weeks post infection suggests an association with liver fluke burden above 45 flukes, which could be used to predict liver pathology in future trials. The results reported in this study highlight the ambiguousness in liver fluke vaccine development and the difficulty in obtaining consistent and repeatable protection. This work stresses the need for repetition of trials and the use of sufficiently sized groups to assess vaccine efficacy with adequate statistical power.
Collapse
Affiliation(s)
- Krystyna Cwiklinski
- Molecular Parasitology Laboratory, Centre for One Health and Ryan Institute, University of Galway, Galway, Ireland; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, UK.
| | - Amanda McEvoy
- Animal & Bioscience Department, Teagasc Mellows Campus, Athenry, Co., Galway, Ireland
| | - Jesús López Corrales
- Molecular Parasitology Laboratory, Centre for One Health and Ryan Institute, University of Galway, Galway, Ireland
| | - Heather Jewhurst
- Molecular Parasitology Laboratory, Centre for One Health and Ryan Institute, University of Galway, Galway, Ireland
| | - Nichola Eliza Davies Calvani
- Molecular Parasitology Laboratory, Centre for One Health and Ryan Institute, University of Galway, Galway, Ireland
| | - Carolina De Marco Verissimo
- Molecular Parasitology Laboratory, Centre for One Health and Ryan Institute, University of Galway, Galway, Ireland
| | - Amber Louise Dorey
- Molecular Parasitology Laboratory, Centre for One Health and Ryan Institute, University of Galway, Galway, Ireland
| | - Orla M Keane
- Animal & Bioscience Department, Teagasc Grange, Dunsany, Co. Meath, Ireland
| | - John Pius Dalton
- Molecular Parasitology Laboratory, Centre for One Health and Ryan Institute, University of Galway, Galway, Ireland
| | - Richard Lalor
- Molecular Parasitology Laboratory, Centre for One Health and Ryan Institute, University of Galway, Galway, Ireland
| |
Collapse
|
3
|
Shcherbak N, Prochaska H, Lystvan K, Prokhorova Y, Giritch A, Kuchuk M. Accumulation of colicin M protein and its biological activity in transgenic lettuce and mizuna plants. FRONTIERS IN PLANT SCIENCE 2023; 14:1271757. [PMID: 37936936 PMCID: PMC10627015 DOI: 10.3389/fpls.2023.1271757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/02/2023] [Accepted: 10/02/2023] [Indexed: 11/09/2023]
Abstract
Food-borne illnesses caused by pathogenic Escherichia coli strains, especially enterohaemorrhagic E. coli (EHEC), are a serious public health problem, as debilitating disease and even death from such food poisonings have been repeatedly reported. Colicin M (ColM), a non-antibiotic antimicrobial protein produced by some strains of E. coli, has shown promising activity in controlling multiple enteropathogenic strains of E. coli and related pathogens. As contaminated green leafy vegetables are a frequent source of pathogenic E. coli infections, we genetically modified (GM) two edible crops, lettuce (Lactuca sativa L.) and mizuna (Brassica rapa subsp. nipposinica var. laciniata), to stably express the ColM gene and assessed the antibacterial activity of tissue extracts from these plants against selected E. coli strains in vitro. Transgenic plants of these species were developed using Agrobacterium-mediated transformation with a vector containing the ColM-coding gene (cma) under the control of the 35S promoter. Western blot analysis of recombinant ColM protein was performed in selected transgenic plants to confirm cma gene expression and quantify ColM accumulation. Extracts of transgenic plants expressing ColM showed significant activity against two major strains of EHEC (O157:H7 and O104:H4) as well as E. coli strains resistant to beta-lactam- and carbapenem-class antibiotics. Importantly, the antibacterial activity persisted in several subsequent generations of transgenic lettuce and mizuna plants that stably expressed the ColM gene. In addition, our results also show that the antibacterial activity of dried (up to 40°C) biomass of transgenic plants remained stable without a decrease for at least three months.
Collapse
Affiliation(s)
- Nataliia Shcherbak
- Department of Genetic Engineering, Institute of Cell Biology and Genetic Engineering of National Academy of Sciences (NAS) of Ukraine, Kyiv, Ukraine
| | | | - Kateryna Lystvan
- Department of Genetic Engineering, Institute of Cell Biology and Genetic Engineering of National Academy of Sciences (NAS) of Ukraine, Kyiv, Ukraine
| | - Yelizaveta Prokhorova
- Department of Genetic Engineering, Institute of Cell Biology and Genetic Engineering of National Academy of Sciences (NAS) of Ukraine, Kyiv, Ukraine
| | | | - Mykola Kuchuk
- Department of Genetic Engineering, Institute of Cell Biology and Genetic Engineering of National Academy of Sciences (NAS) of Ukraine, Kyiv, Ukraine
| |
Collapse
|
4
|
Narayanan Z, Glick BR. Biotechnologically Engineered Plants. BIOLOGY 2023; 12:biology12040601. [PMID: 37106801 PMCID: PMC10135915 DOI: 10.3390/biology12040601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/16/2023] [Revised: 04/08/2023] [Accepted: 04/13/2023] [Indexed: 04/29/2023]
Abstract
The development of recombinant DNA technology during the past thirty years has enabled scientists to isolate, characterize, and manipulate a myriad of different animal, bacterial, and plant genes. This has, in turn, led to the commercialization of hundreds of useful products that have significantly improved human health and well-being. Commercially, these products have been mostly produced in bacterial, fungal, or animal cells grown in culture. More recently, scientists have begun to develop a wide range of transgenic plants that produce numerous useful compounds. The perceived advantage of producing foreign compounds in plants is that compared to other methods of producing these compounds, plants seemingly provide a much less expensive means of production. A few plant-produced compounds are already commercially available; however, many more are in the production pipeline.
Collapse
Affiliation(s)
- Zareen Narayanan
- Division of Biological Sciences, School of STEM, University of Washington, Bothell, WA 98011, USA
| | - Bernard R Glick
- Department of Biology, University of Waterloo, Waterloo, ON N2L3G1, Canada
| |
Collapse
|
5
|
Vilatte A, Spencer-Milnes X, Jackson HO, Purton S, Parker B. Spray Drying Is a Viable Technology for the Preservation of Recombinant Proteins in Microalgae. Microorganisms 2023; 11:microorganisms11020512. [PMID: 36838478 PMCID: PMC9967251 DOI: 10.3390/microorganisms11020512] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2023] [Revised: 01/28/2023] [Accepted: 01/30/2023] [Indexed: 02/22/2023] Open
Abstract
Microalgae are promising host organisms for the production of encapsulated recombinant proteins such as vaccines. However, bottlenecks in bioprocess development, such as the drying stage, need to be addressed to ensure feasibility at scale. In this study, we investigated the potential of spray drying to produce a recombinant vaccine in microalgae. A transformant line of Chlamydomonas reinhardtii carrying a subunit vaccine against salmonid alphavirus was created via chloroplast engineering. The integrity of the recombinant protein after spray drying and its stability after 27 months storage at -80 °C, +4 °C and room temperature were assessed by immunoblotting. The protein withstood spray drying without significant losses. Long-term storage at +4 °C and room temperature resulted in 50% and 92% degradation, respectively. Optimizing spray drying and storage conditions should minimize degradation and favour short-term storage at positive temperatures. Using data on yield and productivity, the economics of spray drying- and freeze drying-based bioprocesses were compared. The drying stage corresponded to 41% of the total production cost. Process optimization, genetic engineering and new market strategies were identified as potential targets for cost reduction. Overall, this study successfully demonstrates the suitability of spray drying as a process option for recombinant protein production in microalgae at the industrial scale.
Collapse
Affiliation(s)
- Anaëlle Vilatte
- Department of Biochemical Engineering, University College London, Gower Street, London WC1E 6BT, UK
| | - Xenia Spencer-Milnes
- Department of Biochemical Engineering, University College London, Gower Street, London WC1E 6BT, UK
- Algal Research Group, Institute of Structural and Molecular Biology, University College London, Gower Street, London WC1E 6BT, UK
| | - Harry Oliver Jackson
- Algal Research Group, Institute of Structural and Molecular Biology, University College London, Gower Street, London WC1E 6BT, UK
| | - Saul Purton
- Algal Research Group, Institute of Structural and Molecular Biology, University College London, Gower Street, London WC1E 6BT, UK
| | - Brenda Parker
- Department of Biochemical Engineering, University College London, Gower Street, London WC1E 6BT, UK
- Correspondence:
| |
Collapse
|
6
|
Wesołowska A. Sex—the most underappreciated variable in research: insights from helminth-infected hosts. Vet Res 2022; 53:94. [PMID: 36397174 PMCID: PMC9672581 DOI: 10.1186/s13567-022-01103-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Accepted: 07/29/2022] [Indexed: 11/18/2022] Open
Abstract
The sex of a host affects the intensity, prevalence, and severity of helminth infection. In many cases, one sex has been found to be more susceptible than the other, with the prevalence and intensity of helminth infections being generally higher among male than female hosts; however, many exceptions exist. This observed sex bias in parasitism results primarily from ecological, behavioural, and physiological differences between males and females. Complex interactions between these influences modulate the risk of infection. Indeed, an interplay among sex hormones, sex chromosomes, the microbiome and the immune system significantly contributes to the generation of sex bias among helminth-infected hosts. However, sex hormones not only can modulate the course of infection but also can be exploited by the parasites, and helminths appear to have developed molecules and pathways for this purpose. Furthermore, host sex may influence the efficacy of anti-helminth vaccines; however, although little data exist regarding this sex-dependent efficacy, host sex is known to influence the response to vaccines. Despite its importance, host sex is frequently overlooked in parasitological studies. This review focuses on the key contributors to sex bias in the case of helminth infection. The precise nature of the mechanisms/factors determining these sex-specific differences generally remains largely unknown, and this represents an obstacle in the development of control methods. There is an urgent need to identify any protective elements that could be targeted in future therapies to provide optimal disease management with regard to host sex. Hence, more research is needed into the impact of host sex on immunity and protection.
Collapse
|
7
|
Cwiklinski K, Drysdale O, López Corrales J, Corripio-Miyar Y, De Marco Verissimo C, Jewhurst H, Smith D, Lalor R, McNeilly TN, Dalton JP. Targeting Secreted Protease/Anti-Protease Balance as a Vaccine Strategy against the Helminth Fasciola hepatica. Vaccines (Basel) 2022; 10:vaccines10020155. [PMID: 35214614 PMCID: PMC8878381 DOI: 10.3390/vaccines10020155] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2021] [Revised: 01/14/2022] [Accepted: 01/18/2022] [Indexed: 02/01/2023] Open
Abstract
The liver fluke Fasciola hepatica is an economically important global pathogen of humans and their livestock. To facilitate host invasion and migration, F. hepatica secretes an abundance of cathepsin peptidases but prevents excessive damage to both parasite and host tissues by co-secreting regulatory peptidase inhibitors, cystatins/stefins and Kunitz-type inhibitors. Here, we report a vaccine strategy aimed at disrupting the parasite’s protease/anti-protease balance by targeting these key inhibitors. Our vaccine cocktail containing three recombinant stefins (rFhStf-1, rFhStf-2, rFhStf-3) and a Kunitz-type inhibitor (rFhKT1) formulated in adjuvant Montanide 61VG was assessed in two independent sheep trials. While fluke burden was not reduced in either trial, in Trial 1 the vaccinated animals showed significantly greater weight gain (p < 0.05) relative to the non-vaccinated control group. In both trials we observed a significant reduction in egg viability (36–42%). Multivariate regression analyses showed vaccination and increased levels of IgG2 antibodies specific for the F. hepatica peptidase inhibitors were positive indicators for increased weight gain and levels of haemoglobin within the normal range at 16 weeks post-infection (wpi; p < 0.05). These studies point to the potential of targeting peptidase inhibitors as vaccine cocktails for fasciolosis control in sheep.
Collapse
Affiliation(s)
- Krystyna Cwiklinski
- Molecular Parasitology Laboratory, Centre for One Health, Ryan Institute, National University of Ireland Galway, H91 DK59 Galway, Ireland; (J.L.C.); (C.D.M.V.); (H.J.); (R.L.); (J.P.D.)
- School of Biological Sciences, Medical Biology Centre, Queen’s University Belfast, Belfast BT9 5DL, UK; (O.D.); (D.S.)
- Correspondence:
| | - Orla Drysdale
- School of Biological Sciences, Medical Biology Centre, Queen’s University Belfast, Belfast BT9 5DL, UK; (O.D.); (D.S.)
| | - Jesús López Corrales
- Molecular Parasitology Laboratory, Centre for One Health, Ryan Institute, National University of Ireland Galway, H91 DK59 Galway, Ireland; (J.L.C.); (C.D.M.V.); (H.J.); (R.L.); (J.P.D.)
| | - Yolanda Corripio-Miyar
- Moredun Research Institute, Pentland Science Park, Penicuik, Midlothian EH26 0PZ, UK; (Y.C.-M.); (T.N.M.)
| | - Carolina De Marco Verissimo
- Molecular Parasitology Laboratory, Centre for One Health, Ryan Institute, National University of Ireland Galway, H91 DK59 Galway, Ireland; (J.L.C.); (C.D.M.V.); (H.J.); (R.L.); (J.P.D.)
- School of Biological Sciences, Medical Biology Centre, Queen’s University Belfast, Belfast BT9 5DL, UK; (O.D.); (D.S.)
| | - Heather Jewhurst
- Molecular Parasitology Laboratory, Centre for One Health, Ryan Institute, National University of Ireland Galway, H91 DK59 Galway, Ireland; (J.L.C.); (C.D.M.V.); (H.J.); (R.L.); (J.P.D.)
- School of Biological Sciences, Medical Biology Centre, Queen’s University Belfast, Belfast BT9 5DL, UK; (O.D.); (D.S.)
| | - David Smith
- School of Biological Sciences, Medical Biology Centre, Queen’s University Belfast, Belfast BT9 5DL, UK; (O.D.); (D.S.)
- Moredun Research Institute, Pentland Science Park, Penicuik, Midlothian EH26 0PZ, UK; (Y.C.-M.); (T.N.M.)
| | - Richard Lalor
- Molecular Parasitology Laboratory, Centre for One Health, Ryan Institute, National University of Ireland Galway, H91 DK59 Galway, Ireland; (J.L.C.); (C.D.M.V.); (H.J.); (R.L.); (J.P.D.)
| | - Tom N. McNeilly
- Moredun Research Institute, Pentland Science Park, Penicuik, Midlothian EH26 0PZ, UK; (Y.C.-M.); (T.N.M.)
| | - John P. Dalton
- Molecular Parasitology Laboratory, Centre for One Health, Ryan Institute, National University of Ireland Galway, H91 DK59 Galway, Ireland; (J.L.C.); (C.D.M.V.); (H.J.); (R.L.); (J.P.D.)
- School of Biological Sciences, Medical Biology Centre, Queen’s University Belfast, Belfast BT9 5DL, UK; (O.D.); (D.S.)
| |
Collapse
|
8
|
Edible vaccines: Current scenario and future prospects. FUTURE FOODS 2022. [DOI: 10.1016/b978-0-323-91001-9.00034-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
9
|
Evaluation of Immunogenicity and Efficacy of Fasciola hepatica Tetraspanin 2 (TSP2) Fused to E. coli Heat-Labile Enterotoxin B Subunit LTB Adjuvant Following Intranasal Vaccination of Cattle. Vaccines (Basel) 2021; 9:vaccines9111213. [PMID: 34835144 PMCID: PMC8623123 DOI: 10.3390/vaccines9111213] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2021] [Revised: 10/15/2021] [Accepted: 10/16/2021] [Indexed: 11/16/2022] Open
Abstract
Fasciolosis, caused by the liver flukes Fasciola hepatica and F. gigantica, is an economically important and globally distributed zoonotic disease. Liver fluke infections in livestock cause significant losses in production and are of particular concern to regions where drug resistance is emerging. Antigens of the F. hepatica surface tegument represent promising vaccine candidates for controlling this disease. Tetraspanins are integral tegumental antigens that have shown partial protection as vaccine candidates against other trematode species. The Escherichia coli heat-labile enterotoxin's B subunit (LTB) is a potent mucosal adjuvant capable of inducing an immune response to fused antigens. This study investigates the potential of F. hepatica tetraspanin 2 extracellular loop 2 (rFhTSP2) as a protective vaccine antigen and determines if fusion of FhTSP2 to LTB can enhance protection in cattle. Cattle were immunised subcutaneously with rFhTSP2 mixed in the Freund's adjuvant and intranasally with rLTB-FhTSP2 in saline, accounting for equal molar ratios of tetraspanin in both groups. Vaccination with rFhTSP2 stimulated a strong specific serum IgG response, whereas there was no significant serum IgG response following rLTB-FhTSP2 intranasal vaccination. There was no substantial antigen specific serum IgA generated in all groups across the trial. Contrastingly, after the fluke challenge, a rise in antigen specific saliva IgA was observed in both vaccination groups on Day 42, with the rLTB-FhTSP2 vaccination group showing significant mucosal IgA production at Day 84. However, neither vaccine group showed a significant reduction of fluke burden nor faecal egg output. These results suggest that intranasal vaccination with rLTB-FhTSP2 does elicit a humoral mucosal response but further work is needed to evaluate if mucosal delivery of liver fluke antigens fused to LTB is a viable vaccine strategy.
Collapse
|
10
|
Zerna G, Spithill TW, Beddoe T. Current Status for Controlling the Overlooked Caprine Fasciolosis. Animals (Basel) 2021; 11:1819. [PMID: 34207215 PMCID: PMC8235714 DOI: 10.3390/ani11061819] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 06/16/2021] [Accepted: 06/16/2021] [Indexed: 01/17/2023] Open
Abstract
The disease fasciolosis is caused by the liver flukes Fasciola hepatica and F. gigantica, which infect a wide range of mammals and production livestock, including goats. These flatworm parasites are globally distributed and predicted to cost the livestock industry a now conservative USD 3 billion per year in treatment and lowered on-farm productivity. Infection poses a risk to animal welfare and results in lowered fertility rates and reduced production yields of meat, milk and wool. This zoonotic disease is estimated to infect over 600 million animals and up to 2.4 million humans. Current and future control is threatened with the global emergence of flukes resistant to anthelmintics. Drug resistance calls for immediate on-farm parasite management to ensure treatments are effective and re-infection rates are kept low, while a sustainable long-term control method, such as a vaccine, is being developed. Despite the recent expansion of the goat industry, particularly in developing countries, there are limited studies on goat-focused vaccine control studies and the effectiveness of drug treatments. There is a requirement to collate caprine-specific fasciolosis knowledge. This review will present the current status of liver fluke caprine infections and potential control methods for application in goat farming.
Collapse
Affiliation(s)
| | | | - Travis Beddoe
- Department of Animal, Plant and Soil Sciences and Centre for AgriBioscience, La Trobe University, Bundoora, Victoria 3083, Australia; (G.Z.); (T.W.S.)
| |
Collapse
|
11
|
Syomin BV, Ilyin YV. Virus-Like Particles as an Instrument of Vaccine Production. Mol Biol 2019; 53:323-334. [PMID: 32214478 PMCID: PMC7088979 DOI: 10.1134/s0026893319030154] [Citation(s) in RCA: 52] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2018] [Revised: 12/19/2018] [Accepted: 12/24/2018] [Indexed: 12/13/2022]
Abstract
The paper discusses the techniques which are currently implemented for vaccine production based on virus-like particles (VLPs). The factors which determine the characteristics of VLP monomers assembly are provided in detail. Analysis of the literature demonstrates that the development of the techniques of VLP production and immobilization of target antigens on their surface have led to the development of universal platforms which make it possible for virtually any known antigen to be exposed on the particle surface in a highly concentrated form. As a result, the focus of attention has shifted from the approaches to VLP production to the development of a precise interface between the organism's immune system and the peptides inducing a strong immune response to pathogens or the organism's own pathological cells. Immunome-specified methods for vaccine design and the prospects of immunoprophylaxis are discussed. Certain examples of vaccines against viral diseases and cancers are considered.
Collapse
Affiliation(s)
- B. V. Syomin
- Institute for Statistical Studies and Economics of Knowledge (ISSEK),
National Research University Higher School of Economics, 101000 Moscow, Russia
| | - Y. V. Ilyin
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia
| |
Collapse
|